Melissa Alsina, MD
Enriched profileAssociate Professor of Medicine, Blood and Marrow Transplant Program; Head, Multiple Myeloma Transplant Program · H. Lee Moffitt Cancer Center & Research Institute
Melissa Alsina is Associate Professor of Medicine, Blood and Marrow Transplant Program; Head, Multiple Myeloma Transplant Program at H. Lee Moffitt Cancer Center & Research Institute. OpenAlex indexes 561 publications with 18,343 citations (h-index 64); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Melissa Alsina, MD, is Associate Professor of Medicine, Blood and Marrow Transplant Program at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. The public record shows 561 publications with 18,343 citations (h-index 64), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 12 companies, 1 NIH-funded awards (2000–2000).
- Most recent indexed publication: 2026 · Cancer research
- Top research focus: Multiple Myeloma Research and Treatments
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 168.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 27 Aug 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year20252 payments
- Janssen Biotech, Inc.Program year20254 payments
- Kite Pharma, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
54.5%Thalidomide Analog52.1%Lenalidomide42%Revlimid35%Pomalyst23%Part D≥23 patientsProteasome Inhibitor2.3%Ninlaro100%Part D<11 patientsDermatology
24.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.1%Acyclovir100%Part D≥45 patientsNervous system
13.4%Opioid Agonist9.4%Oxycodone Hcl39%Tramadol Hcl39%Oxycodone-Acetaminophen23%Part D<11 patientsPhenothiazine2.1%Prochlorperazine Maleate100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2000–2000 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
129 congress contributions (2005–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- AI-enabled multimodal adjudication of revised IMWG progression after BCMA CAR-T.
ASCO Annual Meeting
ASCO2026Co-author - Impact of autoimmune disease on toxicity and outcomes after idecabtagene vicleucel in patients with multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Journal of clinical oncology
Article2025 - Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.
Future oncology (London, England)
Review2025 - The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Cancer research
Article2025
Most-cited works
by citation count (OpenAlex)- 01A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 02
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/melissa-alsina-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Melissa-Alsina-39717659
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
cancernetwork.com/authors/melissa-alsina-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - Other
targetedonc.com/authors/melissa-alsina-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Puerto Rico School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Residency
Internal Medicine, San Juan Veterans Administration Hospital (VA Caribbean Healthcare System)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Fellowship
Hematology, San Juan City Hospital, Puerto Rico
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Fellowship
Medical Oncology/Hematology, University of Texas Health Science Center at San Antonio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Board Certified
Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Member
NCCN Myeloma Guidelines Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Member
NCI Myeloma Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Member
International Myeloma Working Group (IMWG)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myeloma.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Secondary affiliations
appointments beyond the home institution- Formerly Co-Director
Myeloma Bone Disease Program Clinic, UT Health Science Center at San Antonio
1999verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Formerly Assistant Professor of Medicine
South Texas Veterans Health Care System, San Antonio, TX
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ecancer.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- Contributing author
Targeted Oncology (myeloma/immunotherapy commentary)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.